Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
Source abstract
Abstract
The tumor microenvironment (TME), which is mostly composed of tumor cells, immune cells, signaling molecules, stromal tissue, and the vascular system, is an integrated system that is conducive to the formation of tumors. TME heterogeneity makes the response to immunotherapy different in different tumors, such as "immune-cold" and "immune-hot" tumors. Tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells are the major suppressive immune cells and their different phenotypes interact and influence cancer cells by secreting different signaling factors, thus playing a key role in the formation of the TME as well as in the initiation, growth, and metastasis of cancer cells. Nanotechnology development has facilitated overcoming the obstacles that limit the further development of conventional immunotherapy, such as toxic side effects and lack of targeting. In this review, we focus on the role of three major suppressive immune cells in the TME as well as in tumor development, clinical trials of different drugs targeting immune cells, and different attempts to combine drugs with nanomaterials. The aim is to reveal the relationship between immunotherapy, immunosuppressive TME and nanomedicine, thus laying the foundation for further development of immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immune cells in cancer · Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize10.1002/jcb.21187 ↗
2. The tumor microenvironment innately modulates cancer progression10.1158/0008-5472.CAN-18-3962 ↗
3. Modifying the tumour microenvironment and reverting tumour cells: new strategies for treating malignant tumours10.1111/cpr.12865 ↗
4. Stromal cells in the tumor microenvironment10.1007/978-3-319-78127-3_6 ↗
5. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy10.1016/j.apsb.2022.11.001 ↗
6. Sipuleucel-T immunotherapy for castration-resistant prostate cancer10.1056/NEJMoa1001294 ↗
7. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial10.1016/S0140-6736(19)32222-6 ↗
8. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma10.1200/JCO.21.02229 ↗
9. Current progress in CAR-T cell therapy for hematological malignancies10.7150/jca.48976 ↗
10. A review of cancer immunotherapy toxicity
11. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma10.1186/s12943-020-01151-3 ↗
12. Catalytical nano-immunocomplexes for remote-controlled sono-metabolic checkpoint trimodal cancer therapy10.1038/s41467-022-31044-6 ↗
13. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8(+) T cells10.1016/j.biomaterials.2021.120844 ↗
14. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications10.1038/s41423-020-0488-6 ↗
15. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer10.7150/thno.49451 ↗
16. Host tissue determinants of tumour immunity
17. Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization10.1038/s12276-021-00612-z ↗
18. Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation10.1038/s41590-021-00975-5 ↗
19. Epigenetic regulation of T cell exhaustion10.1038/s41590-022-01224-z ↗
20. Protein chips and nanomaterials for application in tumor marker immunoassays10.1016/j.bios.2009.03.020 ↗
21. Therapeutic and diagnostic potential of nanomaterials for enhanced biomedical applications10.1016/j.colsurfb.2019.05.008 ↗
22. Surface modification of gold nanoparticles with small molecules for Biochemical analysis10.1021/acs.accounts.6b00506 ↗
23. Polymeric protective agents for nanoparticles in drug delivery and targeting10.1016/j.ijpharm.2016.03.014 ↗
24. Effect of Oxaliplatin-loaded poly (d,l-Lactide-co-Glycolic acid) (PLGA) nanoparticles combined with retinoic acid and cholesterol on apoptosis, drug resistance, and metastasis factors of colorectal cancer
25. Nanoparticles: properties, applications and toxicities10.1016/j.arabjc.2017.05.011 ↗
26. Engineered multifunctional nano- and biological materials for cancer immunotherapy10.1002/adhm.202001680 ↗
27. Macrophage targeting in cancer10.1111/nyas.14377 ↗
28. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity10.1038/nature22396 ↗
29. Regulatory T cells and immune tolerance10.1016/j.cell.2008.05.009 ↗
30. Ontogeny of tumor-associated macrophages and its implication in cancer regulation10.1016/j.trecan.2015.11.004 ↗
31. Cancers with higher density of tumor-associated macrophages were associated with poor survival rates10.4132/jptm.2015.06.01 ↗
32. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis10.1186/s12943-019-0976-4 ↗
33. Transcriptional regulation of macrophage polarization: enabling diversity with identity10.1038/nri3088 ↗
34. Macrophage activation and polarization: nomenclature and experimental guidelines10.1016/j.immuni.2014.06.008 ↗
35. Biochemical and functional characterization of three activated macrophage populations10.1189/jlb.0406249 ↗
36. NK cells and cancer: you can teach innate cells new tricks10.1038/nrc.2015.5 ↗
37. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion10.1101/gad.1874010 ↗
38. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers10.1182/blood-2010-09-306993 ↗
39. Exosome-guided phenotypic switch of M1 to M2 macrophages for cutaneous wound healing10.1002/advs.201900513 ↗
40. Cell-type-specific responses to interleukin-1 control microbial invasion and tumor-elicited inflammation in colorectal cancer10.1016/j.immuni.2018.11.015 ↗
41. NF-kappaB: linking inflammation and immunity to cancer development and progression10.1038/nri1703 ↗
42. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer10.1016/j.ccr.2009.01.001 ↗
43. EMT transition states during tumor progression and metastasis10.1016/j.tcb.2018.12.001 ↗
44. PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation10.1007/s12282-019-00966-3 ↗
45. Alveolar macrophages drive hepatocellular carcinoma lung metastasis by generating leukotriene B(4)10.4049/jimmunol.1700544 ↗
46. TGF-β-Mediated epithelial-mesenchymal transition and cancer metastasis10.3390/ijms20112767 ↗
47. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis10.1189/jlb.0905495 ↗
48. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis10.1016/j.cellimm.2020.104119 ↗
49. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors10.3390/cancers4030618 ↗
50. Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch10.1242/dev.012187 ↗
51. Macrophage biology in development, homeostasis and disease10.1038/nature12034 ↗
52. Is the C-C motif ligand 2-C-C chemokine receptor 2 Axis a promising target for cancer therapy and diagnosis?10.3390/ijms21239328 ↗
53. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma10.1136/gutjnl-2015-310514 ↗
54. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study10.1007/s11523-014-0320-2 ↗
55. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial10.1016/S1470-2045(16)00078-4 ↗
56. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - the PICCASSO phase I trial10.1016/j.ejca.2022.03.017 ↗
57. Cationic polymeric nanoparticle delivering CCR2 siRNA to inflammatory monocytes for tumor microenvironment modification and cancer therapy10.1021/acs.molpharmaceut.7b00997 ↗
58. Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer10.1039/D0NH00588F ↗
59. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells10.1002/adfm.201501283 ↗
60. Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages10.1021/acsnano.7b05465 ↗
61. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial10.1016/S0140-6736(19)30764-0 ↗
62. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma10.1016/S1470-2045(03)01076-3 ↗
63. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach10.1038/sj.bjc.6603240 ↗
64. Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy10.1016/j.biomaterials.2014.09.007 ↗
65. CSF-1R inhibition alters macrophage polarization and blocks glioma progression10.1038/nm.3337 ↗
66. Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy10.1021/acs.nanolett.7b01193 ↗
67. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas10.1126/science.aad3018 ↗
68. Targeting tumor-associated macrophages by MMP2-sensitive apoptotic body-mimicking nanoparticles10.1021/acsami.0c15983 ↗
69. Specifically eliminating tumor-associated macrophages with an extra- and intracellular stepwise-responsive nanocarrier for inhibiting metastasis10.1021/acsami.0c19301 ↗
70. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles10.1021/mp400216r ↗
71. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity10.1016/j.ijpharm.2017.03.034 ↗
72. CD40-CD40 ligand10.1002/jlb.67.1.2 ↗
73. CD40/CD154 interactions at the interface of tolerance and immunity10.1146/annurev.immunol.22.012703.104533 ↗
74. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study10.1016/S1470-2045(20)30532-5 ↗
75. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody10.1200/JCO.2006.08.3311 ↗
76. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials10.3109/08923973.2014.890626 ↗
77. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis10.1038/19554 ↗
78. Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site10.1038/sj.onc.1201123 ↗
79. Transforming activity of receptor tyrosine kinase tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway10.1182/blood.V95.2.633 ↗
80. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment10.1186/s12943-019-1022-2 ↗
81. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer10.1016/j.ygyno.2021.08.020 ↗
82. 368 reveal: phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
83. ROS-inducing micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy10.1021/acs.biomac.8b00239 ↗
84. M2-Like tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IKKβ siRNA induces M2-to-M1 repolarization for cancer immunotherapy with low immune side effects10.1021/acscentsci.9b01235 ↗
85. Arginase 1 is a key driver of immune suppression in pancreatic cancer10.7554/eLife.80721 ↗
86. Arginase: shedding light on the mechanisms and opportunities in cardiovascular diseases10.1038/s41420-022-01200-4 ↗
87. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers10.1038/s41467-019-11911-5 ↗
88. Reprogramming tumor-associated macrophages to reverse EGFR(T790M) resistance by dual-targeting codelivery of gefitinib/vorinostat10.1021/acs.nanolett.7b03756 ↗
89. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy10.1016/j.jconrel.2011.11.013 ↗
90. A dual macrophage targeting nanovector for delivery of oligodeoxynucleotides to overcome cancer-associated immunosuppression10.1021/acsami.7b13594 ↗
91. Immunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy10.1016/j.biomaterials.2014.08.036 ↗
92. Microglia/brain macrophages as central drivers of brain tumor pathobiology10.1016/j.neuron.2019.08.028 ↗
93. Engineered microparticles for treatment of murine brain metastasis by reprograming tumor microenvironment and inhibiting MAPK pathway10.1002/advs.202206212 ↗
94. Adipocytes encapsulating telratolimod recruit and polarize tumor-associated macrophages for cancer immunotherapy10.1002/advs.202206001 ↗
95. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel10.7150/thno.42385 ↗
96. Injectable shear-thinning polylysine hydrogels for localized immunotherapy of gastric cancer through repolarization of tumor-associated macrophages10.1039/D1BM01053K ↗
97. Nanotechnology-based mRNA vaccines10.1038/s43586-023-00246-7 ↗
98. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
99. mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies10.1002/adma.202007603 ↗
100. Cancer immunotherapy targeting the CD47/SIRPα axis10.1016/j.ejca.2017.02.013 ↗